Cancer Archives

News and Trends 8 Apr 2015

Cardio3, the leading Stem Cell Biotech gets a US patent on CAR-T

Just a week after announcing its intention to launch an IPO in the United States, Cardio3 Biosciences continues increasing its presence in the States. The company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a significant patent application broadly covering TCR-deficient T-Cells engineered to express a chimeric antigen […]

April 8, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 26 Mar 2015

Apceth Initiates Phase II for its pioneering Engineered Cell Therapy to treat Gastrointestinal Cancer

After successfully complete phase I clinical study, apceth initiates the Phase II of world’s first genetically-engineered cell therapy. The ongoing monocentric Phase I/II clinical trial TREAT-ME 1 with the engineered cell therapeutic product Agenmestencel-T, will take place at the Klinikum Grosshadern in Munich. This is the first time that a genetically engineered Mesenchymal Stem Cell […]

March 26, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 25 Mar 2015

Epigenomics’ proColon, the non-invasive blood-based test for colorectal cancer

Epigenomics, the German-American cancer molecular diagnostics company, completed the enrollment for its ADMIT trial (AD herence to Minimally Invasive Testing) for Epi proColon, its non-invasive blood-based test for colorectal cancer (CRC) screening. Epigenomics has successfully completed enrollment in the ADMIT clinical trial this week. Study subjects were identified as historically non-compliant to CRC screening according to […]

March 25, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 24 Mar 2015

Rigontec and its revolutionary RNA-based immunotherapeutics raise €4.8 Million

Rigontec has raised €4.8M in the second closing of its Series A financing round from Forbion Capital Partners, a Dutch life-sciences venture capital firm, and Sunstone Capital, a Copenhagen based venture capital investor. The new investment brings the total Series A to €14.2M to the biopharmaceutical company that is developing RNA-based immunotherapeutics for the treatment of […]

March 24, 2015 - 3 minutesmins - By Lourdes Riquelme

New oncology neoliquid neoplus cancer diagnosis

News and Trends 17 Mar 2015

New Oncology finances its Genetic Test for Cancer Diagnosis

New Oncology completed a financing round to prepare the market launch of NEOliquid, a non-invasive blood test that identifies therapeutically actionable genome alterations in the circulating free tumor DNA (ctDNA) of cancer patients. New Oncology’s pan-cancer diagnostic platform NEOplus reliably detects actionable genome alterations from one single patient sample with short turn-around times. In contrast to […]

March 17, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 Mar 2015

First Treatment Approved under Early Access to Medicine Scheme (EAMS)

Today, it has been accepted! The first drug approved through the Early Access to Medicine Scheme (EAMS), named pembrolizumab, is an immunotherapy treatment for advanced melanoma. The treatment has been developed by Merck, known as MSD outside the United States and Canada, with early development work carried out using MRC Technology’s antibody humanization expertise. EAMS is […]

March 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 10 Mar 2015

The Promising Company OSE Pharma launches an IPO

Created in 2012 by Emile Loria and Dominique Costantini, OSE Pharma is a European cancer immunotherapy company with a multi-epitope technology named Memopi that directs the body’s immune system to generate a specific cytotoxic T response to prevent cancer cell growth. The company announced the launch of its Initial Public Offering (IPO) on Euronext’s regulated […]

March 10, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 9 Mar 2015

MorphoSys and Emergent BioSolutions Initiate Phase I

MorphoSys AG and Emergent BioSolutions will initiate a Phase I clinical study to evaluate the safety, tolerability, and clinical activity of MOR209/ES414 in patients with metastatic castration-resistant prostate cancer (mCRPC). A few months ago, we talked about the beginning of the collaboration between MorphoSys and Emergent BioSolutions. Now, the fruit of their combined work, an […]

March 9, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 5 Mar 2015

Novartis announces completion of transactions with GSK

Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business Sharpens company focus on growing segments of innovative pharmaceuticals, eye care and generics Addition of GSK oncology products and two pipeline compounds is expected to expand Novartis position in targeted therapies and small […]

March 5, 2015 - 5 minutesmins - By Cédric Brock

Bavarian Nordic Bristol Myers Squibb cancer

News and Trends 4 Mar 2015

Bristol-Myers Squibb signs an agreement for Bavarian Nordic’s PROSTVAC

Bristol-Myers Squibb signs an exclusive agreement with Bavarian Nordic for PROSTVAC, a prostate-specific antigen-targeting cancer immunotherapy. Bavarian Nordic will receive up to €880.4M. Bristol-Myers Squibb will have the exclusive option to license and commercialize PROSTVAC, Bavarian Nordic’s investigational Phase III prostate-specific antigen (PSA) in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant […]

March 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 18 Feb 2015

Highway to Brain

Researchers in Barcelona have developed a shuttle to transport drugs into the brain, running through the blood-brain barrier. If there is an irreplaceable organ, for the moment, that’s the brain. The gray matter is not only protected by the skull, but also by a barrier of cells that tightly regulates the transport of substances into this […]

February 18, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 27 Jan 2015

Italian Genenta Science’s Original Strategy to Treat Cancer

Tumor microenvironment, including tumor-associated macrophages, plays a key role in controlling tumor progression and response to therapies. It stimulates tumor growth, supports angiogenesis and tissue remodeling, as well as neutralizes host immunity. Genenta Science is using this mechanism, which is certainly a promising area of cancer biology for the identification of new therapeutic targets. In […]

January 27, 2015 - 2 minutesmins - By Lourdes Riquelme

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Cardio3, the leading Stem Cell Biotech gets a US patent on CAR-T

Apceth Initiates Phase II for its pioneering Engineered Cell Therapy to treat Gastrointestinal Cancer

Epigenomics’ proColon, the non-invasive blood-based test for colorectal cancer

Rigontec and its revolutionary RNA-based immunotherapeutics raise €4.8 Million

New Oncology finances its Genetic Test for Cancer Diagnosis

First Treatment Approved under Early Access to Medicine Scheme (EAMS)

The Promising Company OSE Pharma launches an IPO

MorphoSys and Emergent BioSolutions Initiate Phase I

Novartis announces completion of transactions with GSK

Bristol-Myers Squibb signs an agreement for Bavarian Nordic’s PROSTVAC

Highway to Brain

Italian Genenta Science’s Original Strategy to Treat Cancer

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!